Skip to main content

Advertisement

Table 3 Cox regression analysis of the NV risk at any given age in patients with DMD

From: Influence of β2 adrenergic receptor genotype on risk of nocturnal ventilation in patients with Duchenne muscular dystrophy

  β SE Wald p-value HR 95% CI
Genotype 1.87 0.71 2.66 < 0.05 6.52 1.64–25.99
Age (yrs) −0.57 0.10 −5.55 < 0.05 0.57 0.46–0.69
Ambulatory Status 3.01 0.79 −3.84 < 0.05 0.05 0.01–0.23
Corticosteroid-use (yrs) 0.07 0.05 −1.44 0.15 0.93 0.84–1.03
Weight (cm) 0.02 0.01 2.29 < 0.05 1.02 1.00–1.04
FVC (L) −1.80 0.45 −4.02 < 0.05 0.17 0.07–0.39
  1. SE standard error, HR hazard ratio, CI confidence interval, FVC forced vital capacity, Age: patient age at entry into the study; Arg16: patients who were homozygous or heterozygous for the β2-adrenergic receptor (ADRB2) resulting in at least one arginine substitution at amino acid 16 (n = 26); Gly16: patients who were homozygous for ADRB2 resulting in a glycine substitution at amino acid 16 (n = 147); genotype was coded as: 0 = Arg16, 1 = Gly16; ambulatory status was coded as: 0 = non-ambulatory, 1 = ambulatory; there was a significant influence of genotype, ambulatory status, weight, and FVC on risk of NV use